title: The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.
abstract: Activation of adenosine A2A receptors (A2AR) reduces inflammation by generally inhibiting the activation of pro-inflammatory cells, decreasing endothelial adhesion molecule expression and reducing the release of proinflammatory cytokine mediators. Numerous preclinical studies using selective A2AR agonists, antagonists, A2AR knockout as well as chimeric mice have suggested the therapeutic potential of A2AR agonists for the treatment of ischemia reperfusion injury (IRI) and autoimmune diseases. This review summarizes the immunosuppressive actions of A2AR agonists in murine IRI models of liver, kidney, heart, lung and CNS, and gives details on the cellular effects of A2AR activation in neutrophils, macrophages, dendritic cells, natural killer cells, NKT cells, T effector cells and CD4+CD25+FoxP3+ T regulatory cells. This is discussed in the context of cytokine mediators involved in inflammatory cascades. Whilst the role of adenosine receptor agonists in various models of autoimmune disease has been well-documented, very little information is available regarding the role of A2AR activation in type 1 diabetes mellitus (T1DM). An overview of the pathogenesis of T1DM as well as early islet graft rejection in the immediate peri-transplantation period offers insight regarding the use of A2AR agonists as a beneficial intervention in clinical islet transplantation, promoting islet graft survival, minimizing early islet loss and reducing the number of islets required for successful transplantation, thereby increasing the availability of this procedure to a greater number of recipients. In summary, the use of A2AR agonists as a clinical intervention in IRI and as an adjunct to clinical immunesuppressive regimen in islet transplantation is highlighted.
authors.affiliation: Department of Surgery, University of Virginia School of Medicine, P.O. Box 800709, Charlottesville, VA 22908-0709, USA. klb9r@hscmail.mcc.virginia.edu
authors.forename: Preeti
authors.initials: P
authors.lastname: Chhabra
authors.forename: Joel
authors.initials: J
authors.lastname: Linden
authors.forename: Peter
authors.initials: P
authors.lastname: Lobo
authors.forename: Mark Douglas
authors.initials: MD
authors.lastname: Okusa
authors.forename: Kenneth Lewis
authors.initials: KL
authors.lastname: Brayman
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D007668:Kidney / Q000473:pathology*; D008099:Liver / Q000473:pathology*; D008168:Lung / Q000473:pathology*; D008264:Macrophages / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D009206:Myocardium / Q000473:pathology*; D009504:Neutrophils / Q000276:immunology; D043705:Receptor, Adenosine A2A / Q000276:immunology*; D015427:Reperfusion Injury / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D043705:Receptor, Adenosine A2A